BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9

• 

  Deals

  J&J glows with $1B buyout of Firefly and its degrader platform tech

  The acquisition gives Johnson & Johnson access to Firefly Bio’s next-gen platform designed to create degrader antibody conjugates that can crack the tricky KRAS cancer target.

  June 8, 2026

   · 

  1 min read

   · 

  Gabrielle Masson
• 

  Obesity

  ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold

  Novo Nordisk and Eli Lilly presented data extolling the benefits of their relative weight loss therapies in obesity-linked indications, while analysts at BMO Capital Markets were “encouraged” by the strategy communicated by Novo management.

  June 8, 2026

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Series B

  City Therapeutics builds RNAi pipeline with $99.5M series B

  City Therapeutics, one of BioSpace’s NextGen companies for 2026, was started by RNA royalty John Maraganore, former CEO of Alnylam.

  June 8, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

  June 8, 2026

   · 

  7 min read
• Press Releases

  Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

  June 8, 2026

   · 

  5 min read
• Press Releases

  Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

  June 8, 2026

   · 

  11 min read
• Press Releases

  Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

  June 8, 2026

   · 

  7 min read
• Press Releases

  Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

  June 8, 2026

   · 

  25 min read
• Press Releases

  Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

  June 8, 2026

   · 

  10 min read
• Press Releases

  Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

  June 8, 2026

   · 

  5 min read